1. Home
  2. EZGO vs TPST Comparison

EZGO vs TPST Comparison

Compare EZGO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EZGO Technologies Ltd.

EZGO

EZGO Technologies Ltd.

HOLD

Current Price

$1.25

Market Cap

28.4M

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.26

Market Cap

26.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EZGO
TPST
Founded
2014
2011
Country
China
United States
Employees
N/A
N/A
Industry
Motor Vehicles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.4M
26.2M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
EZGO
TPST
Price
$1.25
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
4.6M
88.4K
Earning Date
07-01-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$1.23
52 Week High
$3.30
$12.22

Technical Indicators

Market Signals
Indicator
EZGO
TPST
Relative Strength Index (RSI) 48.06 30.75
Support Level $0.10 $1.23
Resistance Level $1.32 $2.48
Average True Range (ATR) 0.34 0.07
MACD -0.03 -0.01
Stochastic Oscillator 6.42 5.30

Price Performance

Historical Comparison
EZGO
TPST

About EZGO EZGO Technologies Ltd.

EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: